Biological phenotypes underpin the physio-somatic symptoms of somatization, depression, and chronic fatigue syndrome

Acta Psychiatrica Scandinavica

Volumn 129, Issue 2, 2014, Pages 83-97

  Anderson, G ^a   Berk, M ^b,c,d,e   Maes, M ^b,f,g  

^a CRC   (United Kingdom)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f THAMMASAT UNIVERSITY   (Thailand)

^g CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Autoimmunity; Chronic fatigue syndrome; Cytokines; Depression; Inflammation; Serotonin; Somatization; Tryptophan; Tryptophan catabolite

Indexed keywords

TRYPTOPHAN;

ARTICLE; AUTOIMMUNITY; AUTONOMIC DYSFUNCTION; CHRONIC FATIGUE SYNDROME; DEPRESSION; HUMAN; HYPERALGESIA; INTESTINAL DYSMOTILITY; MALAISE; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; SOMATIZATION;

AUTOIMMUNITY; CHRONIC FATIGUE SYNDROME; CYTOKINES; DEPRESSION; INFLAMMATION; SEROTONIN; SOMATIZATION; TRYPTOPHAN; TRYPTOPHAN CATABOLITE;

AUTOIMMUNITY; BIOLOGICAL MARKERS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FATIGUE SYNDROME, CHRONIC; HUMANS; IMMUNITY, CELLULAR; INFLAMMATION; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION; SOMATOFORM DISORDERS; TRYPTOPHAN;

EID: 84891834559     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12182     Document Type: Article

References (157)

1. Escobar JI, Burnam MA, Karno M, Forsythe A, Golding JM. Somatization in the community. Arch Gen Psychiatry 1987;44:713-718.
2. Rief W, Hessel A, Braehler E. Somatization symptoms and hypochondriacal features in the general population. Psychosom Med 2001;63:595-602.
3. Rief W, Pilger F, Ihle D, Verkerk R, Scharpe S, Maes M. Psychobiological aspects of somatoform disorders: contributions of monoaminergic transmitter systems. Neuropsychobiology 2004;49:24-29.
4. Escobar JI, Rubio-Stipec M, Canino G, Karno M. Somatic symptoms index (SSI): a new and abridged somatization construct - Prevalence and epidemiological correlates in two large community samples. J Nerv Ment Dis 1989;177:140-146.
5. Rief W, Hiller W. Toward empirically based criteria for the classification of somatoform disorders. J Psychosom Res 1999;46:507-518.
6. Dowsett EG, Goudsmit E, Macintyre A, Shepherd CB. London criteria for M.E. In Report from The National Task Force on Chronic Fatigue Syndrome (CFS), Post Viral Fatigue Syndrome (PVFS), Myalgic Encephalomyelitis (ME), Westcare, 1994:96-98.
7. Lane TJ, Manu P, Matthews DA. Depression and somatization in the chronic fatigue syndrome. Am J Med 1991;91:335-344.
8. Martin A, Chalder T, Rief W, Braehler E. The relationship between chronic fatigue and somatization syndrome: a general population survey. J Psychosom Res 2007;63:147-156.
9. Koh KB, Kim DK, Kim SY, Park JK. The relation between anger expression, depression, and somatic symptoms in depressive disorders and somatoform disorders. J Clin Psychiatry 2005;66:485-491.
10. Brown FW, Golding JM, Smith GR Jr. Psychiatric comorbidity in primary care somatization disorder. Psychosom Med 1990;52:445-451.
11. Löwe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008;30:191-199.
12. Alonso Fernández F. Somatoform depressive disorders. An R Acad Nac Med (Madr) 2001;118:745-766.
13. Silverstein B. Gender differences in the prevalence of somatic versus pure depression: a replication. Am J Psychiatry 2002;159:1051-1052.
14. Bschor T. Masked depression: the rise and fall of a diagnosis. Psychiatr Prax 2002;29:207-210.
15. Simon GE, Vonkorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329-1335.
16. Simon GE, Vonkorff M. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Am J Psychiatry 1991;148:1494-1500.
17. Fisch RZ. Masked depression: its interrelations with somatization, hypochondriasis and conversion. Int J Psychiatry Med 1987;17:367-379.
18. Mykletun A, Jacka F, Williams L et al. Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. BMC Gastroenterol 2010;10:88.
19. Hamilton M. The assessment of anxiety by rating. Br J Psychiatry 1959;32:50-55.
20. Mountjoy CQ, Roth M. Studies in the relationship between depressive disorders and anxiety states: part 2: rating scales. J Affect Disord 1982;4:127-147.
21. Maes M. "Functional" or "psychosomatic" symptoms, e.g. a flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett 2009;30:564-573.
22. Robbins JM, Kirmayer LJ. Transient and persistent hypochondriacal worry in primary care. Psychol Med 1996;26:575-589.
23. Kirmayer LJ, Dao THT, Smith A. Somatization and psychologization: understanding cultural idioms of distress. Okpaku S, ed. Clinical methods in transcultural psychiatry. Washington DC: American Psychiatric Press, 1998:233-265.
24. Lipowski ZJ. Somatization and depression. Psychosomatics 1990;31:13-21.
25. Bowlby J. Attachment and loss. Attachment, Vol. 1, London: Hogarth, 1969.
26. Wearden AJ, Lamberton N, Crook N, Walsh V. Adult attachment, alexithymia, and symptom reporting. An extension to the four category model of attachment. J Psychosom Res 2005;58:279-288.
27. Berk M, Berk L, Dodd S et al. Psychometric properties of a scale to measure investment in the sick role: the Illness Cognitions Scale. J Eval Clin Pract 2012;18:360-364.
28. Berk M, Berk L, Dodd S et al. The sick role, illness cognitions and outcomes in bipolar disorder. J Affect Disord 2013;146:146-149.
29. Data-Franco J, Berk M. The nocebo effect: a clinicians guide. Aust N Z J Psychiatry 2013;47:617-623.
30. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
31. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new 5-HT hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:702-721.
32. Burdette SD, Parilo MA, Kaplan LJ, Bailey H. Systemic inflammatory response syndrome. http://emedicine.medscape. com/article/168943-overview. Medscape, eMedicine
33. Maes M. A review on the acute phase response in major depression. Rev Neurosci 1993;4:407-416.
34. Hsuchou H, Kastin AJ, Mishra PK, Pan W. C-Reactive Protein Increases BBB Permeability: Implications for Obesity and Neuroinflammation. Cell Physiol Biochem 2012;30:1109-1119.
35. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-785.
36. Maes M, Bosmans E, Suy E, Vandervorst C, Dejonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991;84:379-386.
37. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression. J Psychosom Res 1997;43:529-534.
38. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
39. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230-239.
40. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171-186.
41. Pasco JA, Nicholson GC, Williams LJ et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010;197:372-377.
42. Maes M, Meltzer HY, Scharpé S et al. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res 1993;47:229-241.
43. Maes M, Mihaylova I, Kubera M, Ringel K. Activation of cell-mediated immunity in depression: association with inflammation, melancholia, clinical staging and the fatigue and somatic symptom cluster of depression. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:169-175.
44. Maes M, Twisk FN. Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010;8:35.
45. Maes M. An intriguing and hitherto unexplained co-occurrence: depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:784-794.
46. Maes M, Twisk FN, Kubera M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord 2012;136:933-939.
47. Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009;8:287-291.
48. Fletcher MA, Zeng XR, Barnes Z, Levis S, Klimas NG. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009;7:96.
49. Meeus M, Nijs J, McGregor N et al. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance. In Vivo 2008;22:115-121.
50. Buchwald D, Wener MH, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 1997;24:372-376.
51. Matsuda J, Gohchi K, Gotoh N. Serum concentrations of 2', 5'-oligoadenylate synthetase, neopterin, and beta-glucan in patients with chronic fatigue syndrome and in patients with major depression. J Neurol Neurosurg Psychiatry 1994;57:1015-1016.
52. Chao CC, Gallagher M, Phair J, Peterson PK. Serum neopterin and interleukin-6 levels in chronic fatigue syndrome. J Infect Dis 1990;162:1412-1413.
53. Nakamura T, Schwander SK, Donnelly R et al. Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia. Clin Vaccine Immunol 2010;17:582-587.
54. Natelson BH, Weaver SA, Tseng CL, Ottenweller JE. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol 2005;12:52-55.
55. Brenu EW, van Driel ML, Staines DR et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011;28:81.
56. Broderick G, Fuite J, Kreitz A, Vernon SD, Klimas N, Fletcher MA. A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 2010;24:1209-1217.
57. Nijs J, Meeus M, McGregor NR et al. Chronic fatigue syndrome: exercise performance related to immune dysfunction. Med Sci Sports Exerc 2005;37:1647-1654.
58. Maes M, Twisk FNM, Ringel K. Inflammatory and cell-mediated immune biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and depression: inflammatory markers higher in ME/CFS than in depression. Psychother Psychosom 2012;81:286-295.
59. Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res 2001;105:165-174.
60. Euteneuer F, Schwarz MJ, Hennings A et al. Psychobiological aspects of somatization syndromes: contributions of inflammatory cytokines and neopterin. Psychiatry Res 2012;195:60-65.
61. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002;43:378-385.
62. Bell IR, Patarca R, Baldwin CM, Klimas NG, Schwartz GE, Hardin EE. Serum neopterin and somatization in women with chemical intolerance, depressives, and normals. Neuropsychobiology 1998;38:13-18.
63. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001;105:45-55.
64. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007;62:207-214.
65. Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes. Psychol Med 2005;35:433-441.
66. Kubera M, Symbirtsev A, Basta-Kaim A et al. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol J Pharmacol 1996;48:503-506.
67. Song C, Horrobin DF, Leonard BE. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry 2006;39:88-99.
68. Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC. Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clin Immunol Immunopathol 1996;81:161-167.
69. Sheng WS, Hu S, Ding JM, Chao CC, Peterson PK. Cytokine expression in the mouse brain in response to immune activation by Corynebacterium parvum. Clin Diagn Lab Immunol 2001;8:446-448.
70. Cavadini G, Petrzilka S, Kohler P et al. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA 2007;104:12843-12848.
71. Carmichael MD, Davis JM, Murphy EA et al. Role of brain macrophages on IL-1beta and fatigue following eccentric exercise-induced muscle damage. Brain Behav Immun 2010;24:564-568.
72. Jiang Y, Deacon R, Anthony DC, Campbell SJ. Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 2008;32:125-132.
73. Maes M, van Gastel A, Delmeire L, Kenis G, Bosmans E, Song C. Platelet alpha2-adrenoceptor density in humans: relationships to stress-induced anxiety, psychasthenic constitution, gender and stress-induced changes in the inflammatory response system. Psychol Med 2002;32:919-928.
74. Hermann GE, Rogers RC. TNFalpha: a trigger of autonomic dysfunction. Neuroscientist 2008;14:53-67.
75. Lacosta S, Merali Z, Anisman H. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety. Behav Neurosci 1999;113:1030-1034.
76. Bianchi M, Panerai AE. Interleukin-2 enhances scopolamine-induced amnesia and hyperactivity in the mouse. NeuroReport 1993;4:1046-1048.
77. Cata JP, Weng HR, Dougherty PM. Spinal injection of IL-2 or IL-15 alters mechanical and thermal withdrawal thresholds in rats. Neurosci Lett 2008;437:45-49.
78. Kerr JR, Barah F, Mattey DL et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 2001;82:3011-3019.
79. Bellmann-Weiler R, Schroecksnadel K, Holzer C, Larcher C, Fuchs D, Weiss G. IFN-gamma mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. J Affect Disord 2008;108:171-176.
80. Maes M, Galecke P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:676-692.
81. Jacka FN, Maes M, Pasco JA, Williams LJ, Berk M. Nutrient intakes and the common mental disorders in women. J Affect Disord 2012;141:79-85.
82. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 2012;135:414-418.
83. Maes M, Ringel K, Kubera M, Berk M, Rybakowski J. Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 2012;136:386-392.
84. Maes M, Ringel K, Kubera M et al. In Myalgic Encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation. J Affect Disord 2013;150:223-230.
85. Hochstrasser T, Ullrich C, Sperner-Unterweger B, Humpel C. Inflammatory stimuli reduce survival of serotonergic neurons and induce neuronal expression of indoleamine 2, 3-dioxygenase in rat dorsal raphe nucleus organotypic brain slices. Neuroscience 2011;184:128-138.
86. Oxenkrug GF. Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 2007;1122:35-49.
87. Liebau C, Baltzer AW, Schmidt S et al. Interleukin-12 and interleukin-18 induce indoleamine 2, 3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 2002;22:931-936.
88. Luchowska E, Kloc R, Olajossy B et al. Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:519-529.
89. Niimi S, Nakamura T, Nawa K, Ichihara A. Hormonal regulation of translatable RNA of tryptophan 2, 3-dioxygenase in primary cultures of adult rat hepatocytes. J Biochem 1983;94:1697-1706.
90. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res 2009;2:1-19.
91. Ren S, Correia MA. Heme: a regulator of rat hepatic tryptophan 2, 3-dioxygenase? Arch Biochem Biophys 2000;377:195-203.
92. Ohira K, Hagihara H, Toyama K et al. Expression of tryptophan 2, 3-dioxygenase in mature granule cells of the adult mouse dentate gyrus. Mol Brain 2010;3:26.
93. Maes M, Meltzer HY, Scharpe S et al. Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993;49:151-165.
94. Maes M, Scharpé S, Meltzer HY et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994;54:143-160.
95. Maes M, Wauters A, Verkerk R et al. Lower serum L-tryptophan availability in depression as a marker of a more generalized disorder in protein metabolism. Neuropsychopharmacology 1996;15:243-251.
96. Møller SE. Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments. Acta Psychiatr Scand 1985;325:(Suppl)3-31.
97. Maes M, Minner B, Suy E. The relationships between the availability of L-tryptophan to the brain, the spontaneous HPA-axis activity, and the HPA-axis responses to dexamethasone in depressed patients. J Amino Acids 1991;1:57-65.
98. Maes M, Vandewoude M, Schotte C et al. The relationships between the cortisol responses to dexamethasone and to L-5-HTP, and the availability of L-tryptophan in depressed females. Biol Psychiatry 1990;27:601-608.
99. Maes M, Jacobs MP, Suy E, Vandewoude M, Minner B, Raus J. Effects of dexamethasone on the availability of L-tryptophan and on the insulin and FFA concentrations in unipolar depressed patients. Biol Psychiatry 1990;27:854-862.
100. Joseph MS, Brewerton TD, Reus VI, Stebbins GT. Plasma L-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Res 1984;11:185-192.
101. Cowen PJ, Parry-Billings M, Newsholme EA. Decreased plasma tryptophan levels in major depression. J Affect Disord 1989;16:27-31.
102. Takikawa O, Yoshida R, Yasui H, Hayaishi O. The relationship between plasma kynurenine and indoleamine 2, 3-dioxygenase activity in the extrahepatic tissues. Schlossberger HG, Kochen W, Linzen B, Steinhart H, eds. Progress in tryptophan and serotonin research. Berlin, New-York: Walter de Gruyter and Co, 1984:517-520.
103. Kanai M, Funakoshi H, Takahashi H et al. Tryptophan 2, 3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2009;2:8.
104. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;98:143-151.
105. Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2, 3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011;32:101-111.
106. Steiner J, Walter M, Gos T et al. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission? J Neuroinflammation 2011;8:94.
107. Vassallo CM, Feldman E, Peto T, Castell L, Sharpley AL, Cowen PJ. Decreased tryptophan availability but normal post-synaptic 5-HT2c receptor sensitivity in chronic fatigue syndrome. Psychol Med 2001;31:585-591.
108. Badawy AA, Morgan CJ, Llewelyn MB, Albuquerque SR, Farmer A. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 2005;19:385-391.
109. Georgiades E, Behan WM, Kilduff LP et al. Chronic fatigue syndrome: new evidence for a central fatigue disorder. Clin Sci (Lond) 2003;105:213-218.
110. Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
111. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-544.
112. Wichers MC, Maes M. The role of indoleamine 2, 3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004;29:11-17.
113. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006;60:77-79.
114. Harvey JA, Schlosberg AJ, Yunger LM. Behavioral correlates of serotonin depletion. Fed Proc 1975;34:1796-1801.
115. Codd EE, Shank RP, Schupsky JJ, Raffa RB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-1270.
116. Maes M, Meltzer HY. The Serotonin Hypothesis of major depression. Selected Chapters on Mood Disorders. Bloom F, Kupfer D, eds. Psychopharmacology, the fourth generation of progress. New York: Raven Press, 1995:933-944.
117. Drummond PD. Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers. Cephalalgia 2006;26:1225-1233.
118. Struzik L, Duffin J, Vermani M, Hegadoren K, Katzman MA. Effects of tryptophan depletion on central and peripheral chemoreflexes in man. Respir Physiol Neurobiol 2002;133:183-195.
119. van Veen JF, van Vliet IM, de Rijk RH et al. Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. Psychoneuroendocrinology 2009;34:1590-1594.
120. Kilkens TO, Honig A, van Nieuwenhoven MA, Riedel WJ, Brummer RJ. Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controls. Gut 2004;53:1794-1800.
121. Booij L, Swenne CA, Brosschot JF, Haffmans PM, Thayer JF, van der Does AJ. Tryptophan depletion affects heart rate variability and impulsivity in remitted depressed patients with a history of suicidal ideation. Biol Psychiatry 2006;60:507-514.
122. Zepf FD, Holtmann M, Stadler C, Wöckel L, Poustka F. Reduced serotonergic functioning changes heart rate in ADHD. J Neural Transm 2009;116:105-108.
123. Davies SJ, Hood SD, Argyropoulos SV et al. Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J Clin Psychopharmacol 2006;26:414-418.
124. Richell RA, Deakin JF, Anderson IM. Effect of acute tryptophan depletion on the response to controllable and uncontrollable noise stress. Biol Psychiatry 2005;57:295-300.
125. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2001;(3):CD003198. Review. Update in: Cochrane Database Syst Rev. 2002;00(1):CD003198.
126. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002;1:609-620.
127. Huengsberg M, Winer J, Round R, Gompels M, Shahmanesh M. Elevated serum kynurenine level is associated with peripheral neuropathy in HIV. Neuroscience of HIV Infection. J Neurovirol 1998;4:353.
128. Kaszaki J, Palásthy Z, Erczes D et al. Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil 2008;20:53-62.
129. Wu LJ, Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics 2009;6:693-702.
130. Cairns BE, Svensson P, Wang K et al. Activation of peripheral NMDA receptors contributes to human pain and rat afferent discharges evoked by injection of glutamate into the masseter muscle. J Neurophysiol 2003;90:2098-2105.
131. McRoberts JA, Coutinho SV, Marvizón JC et al. Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001;120:1737-1748.
132. Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990;10:2965-2973.
133. Wang J, Simonavicius N, Wu X et al. Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35. J Biol Chem 2006;281:22021-22028.
134. Cosi C, Mannaioni G, Cozzi A et al. G-protein coupled receptor 35 (GPR35) activation and inflammatory pain: Studies on the antinociceptive effects of kynurenic acid and zaprinast. Neuropharmacology 2011;60:1227-1231.
135. Ting KK, Brew BJ, Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation 2009;6:36.
136. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 2009;16:77-86.
137. Lapin IP. Anxiogenic activity of quinolinic acid and kynurenine in the social interaction test in mice. J Psychopharmacol 1996;10:246-249.
138. Vécsei L, Beal MF. Influence of kynurenine treatment on open-field activity, elevated plus-maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav 1990;37:71-76.
139. Orlikov A, Ryzov I. Caffeine-induced anxiety and increase of kynurenine concentration in plasma of healthy subjects: a pilot study. Biol Psychiatry 1991;29:391-396.
140. Orlikov AB, Prakhe IB, Ryzhov IV. Plasma kynurenine levels and the dexamethasone test in patients with endogenous anxiety disorders and depression. Zh Nevropatol Psikhiatr Im S S Korsakova 1990;90:83-85.
141. Lapin IP. Antagonism of kynurenic acid to anxiogens in mice. Life Sci 1998;63:231-236.
142. Schmitt ML, Graeff FG, Carobrez AP. Anxiolytic effect of kynurenic acid microinjected into the dorsal periaqueductal gray matter of rats placed in the elevated plus-maze test. Braz J Med Biol Res 1990;23:677-679.
143. Németh H, Toldi J, Vécsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res 2005;2:249-260.
144. Picciotto MR, Zoli M, Léna C et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995;374:65-67.
145. Boess FG, de Vry J, Erb C et al. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007;321:716-725.
146. Loram LC, Taylor FR, Strand KA et al. Systemic administration of an alpha-7 nicotinic acetylcholine agonist reverses neuropathic pain in male sprague dawley rats. J Pain 2012;13:1162-1171.
147. Markus RP, Silva CLM, Franco DG, Barbosa EM Jr, Ferreira ZS. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol Ther 2010;126:251-262.
148. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012;196:243-249.
149. Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry 2013;42:101-141.
150. Anderson G, Maes M. Metabolic syndrome, Alzheimer's, schizophrenia and depression: role for leptin, melatonin, kynurenine pathways and neuropeptides. Farooqui T, Farooqui AA, eds. Metabolic syndrome and neurological disorders. New York: Wiley, 2013:235-248.
151. Anderson G. Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 2011;76:54-60.
152. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407-414.
153. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
154. Maes M, Berk M, Goehler L et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 2012;10:66.
155. Straub RH. Evolutionary medicine and chronic inflammatory state-known and new concepts in pathophysiology. J Mol Med (Berl) 2012;90:523-534.
156. Morris G, Anderson G, Galecki P, Berk M, Maes M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med 2013;11:64.
157. Simpson HB. The RDoC project: a new paradigm for investigating the pathophysiology of anxiety. Depress Anxiety 2012;29:251-252.